FibroBiologics, Inc.

FibroBiologics, Inc. reported a net loss of $4.1 million for Q2 2026, an improvement from $4.7 million in Q2 2025, and a net loss of $9.1 million for the six months ended June 30, 2026. Despite the reduced losses, the company's cash and cash equivalents decreased to $3.5 million as of June 30, 2026, from $4.9 million at year-end 2025. Management has raised substantial doubt about the company's ability to continue as a going concern due to ongoing operating losses and reliance on additional capital.

FibroBiologics, Inc. is holding a Special Meeting on September 17, 2026, to seek stockholder approval for the issuance of up to 8,163,266 shares of common stock upon the exercise of outstanding warrants from a June 2026 Securities Purchase Agreement, and an additional 285,714 shares for placement agent warrants. This approval is required under Nasdaq Listing Rule 5635(d) because the potential issuance exceeds 20% of outstanding shares. The Board recommends approval, noting that failure to do so could result in liquidated damages and significant legal expenses, while approval could bring in approximately $6.26 million from warrant exercises.

FibroBiologics, Inc. received a Staff Determination letter from Nasdaq on July 22, 2026, notifying the company of its securities' delisting from The Nasdaq Capital Market. This is due to the company's bid price closing below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The company is not eligible for a compliance period due to a reverse stock split within the past year. FibroBiologics intends to appeal the determination by requesting a hearing before a Nasdaq Hearings Panel.

FibroBiologics, Inc. announced a change to its Board of Directors. Matt Link resigned from the Board, effective July 2, 2026. Subsequently, on July 8, 2026, the Board appointed Dr. Kathleen Rubins as a Class III director. Dr. Rubins, a retired NASA astronaut and microbiologist, will also serve on the Audit, Compensation, and Governance and Nominating Committees, bringing significant scientific and leadership expertise to the company.

FibroBiologics, Inc. announced the closing of a private placement offering, generating $3.0 million in gross proceeds. The offering included pre-funded warrants and common stock warrants, with the potential to raise an additional $6.0 million if all warrants are exercised. The net proceeds of approximately $2.6 million from the initial closing will be used for working capital and general corporate purposes. H.C. Wainwright & Co. served as the exclusive placement agent for the transaction.

FibroBiologics, Inc. stockholders approved the 2026 Equity and Incentive Compensation Plan, which succeeds the 2022 Stock Plan. The new plan makes 2,061,968 shares available for awards, with an "evergreen" provision to increase shares annually. Additionally, stockholders elected Pete O’Heeron as a Class III director to serve until the 2029 Annual Meeting and ratified WithumSmith+Brown, PC as the independent registered public accounting firm for 2026.

FibroBiologics, Inc. announced that the first patients have been dosed in its Phase 1/2 clinical trial evaluating CYWC628 for the treatment of diabetic foot ulcers (DFUs). This marks a significant transition from laboratory science to clinical application for the investigational allogeneic fibroblast cell-based therapy. Concurrently, the company is advancing its manufacturing operations, having released drug product from its second good manufacturing practice (GMP) run and completed the first two batches of its third GMP run to support ongoing trial activity.

FibroBiologics announced positive preclinical data for its CYPS317 program for psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting. The data showed that HDF spheroids reduced disease severity in mouse models, offered a favorable systemic safety profile, and sustained therapeutic efficacy with booster dosing. CYPS317 also demonstrated significant reductions in PASI scores and protected against hallmarks of psoriatic disease, indicating targeted immunomodulation.

FibroBiologics, Inc. announced a strategic expansion of its fibroblast-based platform to target Hantavirus pulmonary syndrome (HPS). This initiative builds on existing preclinical work in treating acute respiratory distress syndrome (ARDS), which shares similar terminal lung damage and inflammatory cascades with HPS. HPS is a rare but severe respiratory illness with high mortality rates and no approved antiviral therapies. The company's fibroblast platform is designed to modulate uncontrolled inflammatory responses and promote tissue repair, and FibroBiologics is now evaluating its platform in Hantavirus disease models with plans for regulatory discussions.

FibroBiologics, Inc. announced an increase in its At The Market (ATM) offering program, raising the maximum aggregate offering price to up to $7,500,000. This ATM offering, established on May 1, 2026, allows the company to sell common stock through H.C. Wainwright & Co., LLC. To date, 71,830 shares have been sold under the agreement.